1 / 5

Reviewer: Dr Sunil Verma Date posted: June 21, 2007

Five Year Update of Cardiac Dysfunction in NSABP B-31 A Randomized Trial of AC  Paclitaxel vs. AC Paclitaxel with Trastuzumab in HER2- Postive, Node Positive, Operable Breast Cancer Authors: Rastogi et al. Reviewer: Dr Sunil Verma Date posted: June 21, 2007. Treatment A: AC q3wk x 4

tuvya
Download Presentation

Reviewer: Dr Sunil Verma Date posted: June 21, 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Five Year Update of Cardiac Dysfunction in NSABP B-31A Randomized Trial of AC Paclitaxel vs. AC Paclitaxel with Trastuzumab in HER2- Postive, Node Positive, Operable Breast CancerAuthors: Rastogi et al. Reviewer: Dr Sunil Verma Date posted: June 21, 2007

  2. Treatment A: AC q3wk x 4 Paclitaxel q3wk x 4* or Paclitaxel qwk x 12* R Treatment B: AC q3wk x 4 Paclitaxel q3wk x 4* Or Paclitaxel qwk x 12* + Trastuzumab qwk x 52 Operable breast\ cancer Her-2Positive tumour Pathological Positive Axillary nodes

  3. RESULTS • About 6.5% of patients randomized to the Herceptin containing arm did not receive Herceptin related to cardiac dysfunction with four cycles of AC • 3 year data (previously reported) on Cardiac Events • No herceptin 0.8% • Herceptin 4.1% • 5 year update (current presentation at ASCO 2007) • No herceptin 0.9% • Herceptin 3.8% • The following factors were found to be predictive for cardiac toxicity • Age • Use of Hypertension medications • LVEF

  4. STUDY COMMENTARY • This was a 5 year update on cardiac toxicity associated with Herceptin as per the NSABP B-31 Trial • There doesn’t seem to be increased cardiac toxicity with longer follow-up • There was a predictive model presented to better predict the risk of cardiac toxicity

  5. BOTTOM LINE FOR CANADIAN MEDICAL ONCOLOGISTS • It is important to address modifiable cardiac risk factors prior to initiating therapy • The risk of cardiac toxicity is dependent of many patient related factors • It is prudent to review these factors in the context of tumor profile and make the decision on the need for Herceptin on an individual basis • Long term follow up is still needed as most of these cardiac events may occur later • We still don’t know the long term effect of asymptomatic LV dysfunction

More Related